查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1840889

胃食道逆流症治疗市场（按治疗类型、通路、给药途径、剂型和患者最终用户划分）－全球预测 2025-2032

Gastroesophageal Reflux Disease Therapeutics Market by Treatment Type, Distribution Channel, Route Of Administration, Dosage Form, Patient End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，胃食道逆流症药物市场将成长至 91.8 亿美元，复合年增长率为 5.16%。

主要市场统计数据
基准年2024年 61.4亿美元
预计2025年 64.5亿美元
预测年份：2032年 91.8亿美元
复合年增长率（%） 5.16%

简洁而全面地介绍不断发展的治疗前景、临床驱动因素、患者需求以及影响 GERD 治疗的策略重点

由于持续的症状负担、不断发展的临床路径以及不断变化的患者期​​望，胃食道逆流症 (GERD) 已成为消化器官系统保健领域的核心。现代临床实践在长期确立的抑酸疗法与更注重长期安全性、按需治疗以及辅助性机械和内视镜干预措施之间取得了平衡。因此，临床、商业和监管相关人员正在重新评估治疗重点和投资决策。

因此，临床医师越来越注重区分患者的表型、优化诊断流程，并根据症状模式和疗效制定个人化治疗方案。治疗方案的重大转变、新型抑酸药物的兴起以及微创手术的普及，正在拓宽治疗频谱，但同时又不影响实证药物治疗的核心作用。同时，支付方监管、学名药竞争和门诊病人管理等方面的趋势正在重塑处方和分销行为。

这些综合动态为产品开发商、製造商和医疗保健系统带来了复杂性和机会。因此，清晰的策略需要综合考虑临床趋势、供应链现状和以​​患者为中心的交付模式，从而做出切实可行的决策，在改善疗效的同时保持商业性可行性。

透过药物创新、程序介入、以患者为中心的数位解决方案和诊断，重新定义 GERD 治疗途径的转型转变

随着技术创新的融合、医疗服务模式的不断变化以及人们对安全性和个人化治疗期望的不断提高，胃食道逆流症 (GERD) 的治疗格局正在改变。在药理学方面，新型抑酸剂和替代机制的出现迫使临床医生重新思考长期治疗策略，而越来越多的证据和特定市场的监管核准正在推出超越传统质子帮浦阻断剂的具有临床意义的治疗方案。同时，微创和器械介导治疗方法正从小众转诊中心走向更广泛的临床应用，为寻求缓解难治性疾病和药物依赖的患者提供新的治疗选择。

同时，诊断技术也日益精细化，门诊和电阻监测的增强促进了表型主导的治疗。支持依从性、症状追踪和远端医疗咨询的数位化工具正在重塑持续护理，并实现更快速的治疗滴定。此外，学名药与品牌药创新之间的相互作用正在推动策略性产品组合调整、伙伴关係模式和上市策略。因此，製造商和医疗保健提供者必须应对一个多维度的环境，在这个环境中，临床差异化、成本效益和患者体验决定了药物的吸收和持续使用。

对 2025 年关税转变将如何重塑 GERD 的供应链、筹资策略以及整个价值链的商业性决策进行基于证据的评估

贸易政策发展，包括2025年生效的关税调整，将产生累积压力，波及药品生产、分销和采购领域。原料、活性药物成分、设备零件和包装的关税可能会提高投入成本，对利润微薄的学名药和品牌药製造商构成挑战。为此，许多公司正在加速供应商多元化，增加对区域製造地的依赖，并寻求更长期的合约保护，以稳定关键投入品的取得。

因此，采购团队和商业领袖正在重新评估其采购布局，以降低进口关税和运输波动带来的风险。对于专业医疗设备和契约製造而言，关税驱动的成本上涨促使他们在法规和工作条件允许的情况下更倾向于近岸或在岸生产，儘管资本和技术限制可能会限制短期转移。从分销角度来看，由于成本上涨与付款方对可负担性和基于价值的合约的预期相交织，医院处方集和门诊护理提供者可能面临与供应商谈判的更大压力。

综上所述，这些动态凸显了主动的供应链风险评估、情境规划和策略供应商伙伴关係关係对于减轻关税影响的重要性。在日益复杂的贸易环境中，投资供应链透明度、自适应采购和库存优化的公司将能够保持临床连续性，同时保护商业性利润。

将治疗方式、分销管道、给药途径和形式以及患者最终用户情况与策略重点联繫起来的细分主导洞察

该细分提供了一个框架，用于将治疗方法开发、商业策略和分销策略与患者需求和临床环境相结合。根据治疗类型，市场分为制酸剂、H2受体拮抗剂、促动力剂和质子帮浦阻断剂。 H2受体拮抗剂进一步分为品牌药和学名药。质子帮浦阻断剂进一步分为品牌药和学名药。这种治疗水准的细分突显了速效非处方药、按需处方药和长效抑制疗法的共存，突显了创新和配方改良可以创造临床优势的领域。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 增加钾竞争性酸阻断剂在难治性胃食道逆流症患者的临床应用
  • 整合人工智慧驱动的数位健康平台，用于远端监控和 GERD 治疗的依从性
  • 微创内视镜抗逆流方法（如 TIF 和 MSA）在临床上的广泛应用
  • 新兴微生物组标靶治疗策略作为GERD管理的辅助方法
  • 利用遗传生物标记的个人化治疗流程优化 GERD 治疗结果

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 胃食道逆流症治疗药物市场（依治疗类型）

  • 制酸剂
  • H2受体拮抗剂
    • 品牌
    • 非专利的
  • 促动力
  • 质子帮浦抑制剂
    • 品牌
    • 非专利的

9. 胃食道逆流症药物市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

10. 胃食道逆流症药物市场（依给药途径）

  • 静脉
  • 口服

第11章胃食道逆流症治疗市场（按剂型）

  • 胶囊
  • 液体
  • 暂停
  • 药片

12. GERD药物市场患者最终用户

  • 居家照护环境
  • 医院
  • 专科诊所

13. GERD治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章胃食道逆流症药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. GERD治疗市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AstraZeneca PLC
    • Takeda Pharmaceutical Company Limited
    • Johnson & Johnson Services, Inc.
    • Pfizer Inc.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Bayer AG
    • Merck Sharp & Dohme Corp.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-AD36CD897D13

The Gastroesophageal Reflux Disease Therapeutics Market is projected to grow by USD 9.18 billion at a CAGR of 5.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.14 billion
Estimated Year [2025] USD 6.45 billion
Forecast Year [2032] USD 9.18 billion
CAGR (%) 5.16%

A concise yet comprehensive introduction to the evolving therapeutic landscape, clinical drivers, patient needs, and strategic priorities shaping GERD treatments

Gastroesophageal reflux disease occupies a central position in digestive healthcare, driven by persistent symptom burden, evolving clinical pathways, and shifting patient expectations. In recent years clinical practice has balanced long-established acid suppression approaches with growing attention to long-term safety, on-demand management, and complementary mechanical or endoscopic interventions. As a result, stakeholders across clinical, commercial, and regulatory spheres are reassessing therapeutic priorities and investment decisions.

Consequently, clinicians are increasingly focused on differentiating patient phenotypes, optimizing diagnostic algorithms, and tailoring treatments to symptom patterns and treatment response. Pivotal changes in therapeutic options, the rise of novel acid suppression classes, and broader access to minimally invasive procedures have widened the spectrum of care without eliminating the central role of evidence-based pharmacotherapy. At the same time, payer scrutiny, generics competition, and outpatient management trends are reshaping prescribing and distribution behaviors.

Taken together, these dynamics create both complexity and opportunity for product developers, manufacturers, and health systems. Therefore, strategic clarity requires an integrated view that connects clinical trends, supply chain realities, and patient-centered delivery models to inform pragmatic decisions that enhance outcomes while maintaining commercial viability.

Transformative shifts redefining GERD care pathways through pharmacologic innovation, procedural interventions, and patient-centric digital solutions and diagnostics

The GERD therapeutic landscape is undergoing transformative shifts as innovation converges with changing care delivery models and heightened expectations for safety and personalization. On the pharmacologic front, new classes of acid suppression and alternative mechanisms are prompting clinicians to reconsider long-term management strategies, while growing evidence and regulatory approvals in select markets have introduced clinically meaningful options beyond traditional proton pump inhibitors. In parallel, minimally invasive and device-mediated procedures have moved from niche referral centers toward broader clinical adoption, offering alternatives for refractory disease and patients seeking reduced pharmacologic dependence.

Meanwhile, diagnostics are becoming more nuanced, with enhanced ambulatory and impedance monitoring facilitating phenotype-driven therapy. Digital tools that support adherence, symptom tracking, and telehealth consultations are reshaping continuity of care and enabling more responsive titration of therapies. Moreover, the interplay between generics and branded innovation is driving strategic portfolio adjustments, partnership models, and go-to-market approaches. As a result, manufacturers and providers must navigate a multidimensional environment where clinical differentiation, cost-effectiveness, and patient experience determine uptake and sustained use.

An evidence-based appraisal of how 2025 tariff shifts cumulatively reshape GERD supply chains, procurement strategies, and commercial decision-making across the value chain

Trade policy developments, including tariff adjustments implemented during 2025, introduce cumulative pressures that reverberate across pharmaceutical manufacturing, distribution, and procurement. Tariffs on raw materials, active pharmaceutical ingredients, device components, and packaging can elevate input costs, thereby challenging manufacturers that operate on narrow margins in generic and branded segments alike. In response, many organizations accelerate supplier diversification, increase reliance on regional manufacturing hubs, and pursue longer-term contractual protections to stabilize access to critical inputs.

Consequently, procurement teams and commercial leaders are reassessing sourcing footprints to reduce exposure to import duties and transportation volatility. For specialty devices and contract manufacturing, tariff-induced cost increases tend to favor near-shore or onshore production where regulatory and labor conditions permit, though capital and technical constraints can limit near-term shifts. From a distribution perspective, hospital formularies and outpatient providers may face heightened negotiation pressure with suppliers as cost escalation intersects with payer expectations for affordability and value-based contracting.

Taken together, these dynamics highlight the importance of proactive supply chain risk assessment, scenario planning, and strategic supplier partnerships to mitigate tariff impacts. Firms that invest in supply chain transparency, adaptive sourcing, and inventory optimization can preserve clinical continuity while protecting commercial margins in an increasingly complex trade environment.

Segment-driven insights that connect treatment modalities, distribution channels, routes and forms of administration, and patient end-user contexts to strategic priorities

Segmentation provides the framework to align therapeutic development, commercial tactics, and distribution strategies with patient needs and clinical settings. Based on Treatment Type, market is studied across Antacids, H2 Receptor Antagonists, Prokinetics, and Proton Pump Inhibitors. The H2 Receptor Antagonists is further studied across Branded and Generic. The Proton Pump Inhibitors is further studied across Branded and Generic. This treatment-level granularity underscores the coexistence of rapid-onset OTC options, on-demand prescriptions, and durable suppression therapies, and it clarifies where innovation or reformulation can create clinical advantage.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. This distribution perspective reveals differential access patterns for acute inpatient care versus chronic outpatient management, and it highlights the growing importance of e-commerce for therapy continuity and adherence. Based on Route Of Administration, market is studied across Intravenous and Oral. Intravenous formulations remain critical for perioperative and hospitalized patients, while oral therapies dominate ambulatory care and home treatment strategies. Based on Dosage Form, market is studied across Capsule, Liquid, Suspension, and Tablet. Dosage form diversity supports age- and comorbidity-appropriate prescribing and adherence initiatives, particularly for pediatric, geriatric, and dysphagia-prone populations. Based on Patient End User, market is studied across Home Care Settings, Hospitals, and Specialty Clinics. Understanding end-user dynamics guides commercial outreach, patient support programs, and clinical education to ensure therapy alignment with care settings and patient expectations.

Therefore, segmentation-led insight enables targeted R&D prioritization, precise channel strategies, and tailored clinical support that collectively improve uptake and patient outcomes.

Regional clinical, regulatory, and supply chain nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that define differentiated strategic imperatives

Regional dynamics materially influence clinical practice patterns, regulatory timelines, and supply chain architectures, creating differentiated strategic imperatives across the globe. In the Americas, clinical practice is characterized by widespread adoption of established acid-suppression therapies, growing outpatient management, and a competitive landscape that incentivizes both branded differentiation and generic efficiency. Health systems and payers often emphasize real-world outcomes and formulary alignment, which in turn shapes provider prescribing and manufacturer access strategies.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable healthcare infrastructures demand regionally adapted approaches. Some countries prioritize value assessments and cost-effectiveness, while others emphasize access and primary care management. Consequently, manufacturers must align dossier development, pricing strategies, and local market partnerships to navigate reimbursement pathways and cultivate specialist referral networks. In Asia-Pacific, rapid urbanization, changing dietary patterns, and shifting diagnostic awareness have influenced prevalence and treatment demand. Additionally, certain markets in the region have been early adopters of new acid-suppression technologies, and manufacturing capacity in Asia-Pacific remains a strategic asset for both regional supply and global export.

Across these regions, regulatory trends, clinical guideline updates, and tariff considerations interact to influence launch sequencing, procurement planning, and local commercial models. Recognizing these regional nuances enables more precise investment prioritization and executional planning.

Strategic behaviors and competitive positioning among pharmaceutical, device, and manufacturing stakeholders that determine commercial and clinical success in GERD therapeutics

Companies operating in the GERD therapeutics space are pursuing a spectrum of strategic moves to preserve competitiveness and capture clinical relevance. Established pharmaceutical firms are balancing lifecycle management for long-standing acid-suppression products with selective investments in novel mechanisms and reformulations that address safety, adherence, and on-demand use. Generic manufacturers continue to optimize cost structures and expand distribution partnerships to maintain penetration across retail and hospital channels, while specialized device companies focus on clinical evidence generation to broaden adoption of endoscopic and implantable solutions.

Additionally, contract development and manufacturing organizations play an increasingly pivotal role as companies seek flexible, regulatory-compliant production capacity that supports both oral and intravenous forms across multiple dosage formats. Strategic collaborations between pharmaceutical developers and digital health vendors are emerging to create patient support ecosystems that improve adherence and capture real-world data. In parallel, commercial teams are refining payer engagement strategies to emphasize value-based outcomes and to secure formulary positioning amid heightened cost scrutiny. Collectively, these organizational approaches reflect an ecosystem where clinical differentiation, evidence generation, and operational resilience determine long-term success.

Actionable recommendations for leaders to strengthen supply chains, clinical differentiation, payer engagement, digital support, and regulatory alignment in GERD care

Industry leaders should adopt a multi-pronged strategy that aligns clinical innovation with operational resilience and market-facing agility. First, prioritize diversified and resilient supply chains by qualifying alternate suppliers for key APIs and components, investing in regional manufacturing partnerships, and implementing advanced inventory and demand-sensing capabilities to mitigate tariff and logistics volatility. Second, advance therapeutic differentiation by investing in clinical programs that clarify patient phenotypes, demonstrate comparative safety for long-term use, and evaluate combination or adjunctive approaches that reduce dependence on chronic high-dose acid suppression.

Third, strengthen payer and provider engagement through real-world evidence programs, outcomes-based contracting pilots, and targeted educational initiatives aimed at specialty clinics and hospital formularies to communicate value propositions effectively. Fourth, accelerate digital and patient support offerings that enhance adherence, personalized dosing, and telehealth integration, thereby improving outcomes and reducing unnecessary escalation to invasive procedures. Fifth, tailor commercial models across distribution channels by optimizing online pharmacy partnerships for chronic therapy continuity while maintaining hospital and retail access for acute and inpatient settings. Finally, ensure regulatory alignment by proactively engaging authorities on labeling, safety monitoring, and post-market evidence generation to facilitate access and maintain clinician confidence.

By executing these recommendations concurrently, organizations can protect margins, enhance patient outcomes, and sustain competitive advantage in a rapidly evolving therapeutic landscape.

A robust mixed-methods research methodology combining expert interviews, literature synthesis, supply chain mapping, and scenario analysis to validate insights and recommendations

The analysis underpinning this executive summary integrates a mixed-methods research approach to ensure depth, validity, and practical relevance. Primary qualitative inputs include structured interviews with clinical key opinion leaders, hospital pharmacists, specialty clinic directors, and senior procurement professionals to capture frontline perspectives on prescribing behavior, device adoption, and supply chain risks. Secondary research synthesized peer-reviewed literature, clinical guideline updates, public regulatory filings, and product monographs to validate therapeutic mechanisms, recent approvals, and diagnostic advancements.

Operational and commercial dimensions were examined through supply chain mapping exercises, review of import/export exposure, and scenario-based tariff impact modeling to identify stress points and mitigation options. Data triangulation methods were applied to reconcile divergent inputs and to ensure consistent interpretation across clinical, regulatory, and commercial domains. Finally, stakeholder validation workshops were conducted to refine conclusions, stress-test recommendations, and align insights with pragmatic implementation pathways for manufacturers, providers, and distributors.

This methodological blend of qualitative and quantitative techniques delivers a holistic perspective designed to support strategic decision-making without relying solely on single-source data points.

A concise conclusion highlighting emerging opportunities, operational challenges, and the integrated priorities that will shape future GERD therapeutic strategies

In summary, the GERD therapeutics ecosystem is characterized by steady clinical demand, meaningful innovation, and mounting operational complexity. Novel pharmacologic classes and minimally invasive procedures expand treatment choices, while evolving diagnostics and digital tools enable more precise, patient-centered care. At the same time, commercial and supply chain pressures, including tariff dynamics and distribution shifts, require companies to rethink sourcing, manufacturing footprints, and channel engagement.

Looking ahead, sustained success will depend on the ability to integrate clinical differentiation with resilient operations and evidence-led payer discussions. Organizations that invest in targeted clinical programs, diversify supply chains, and deploy digital adherence solutions will be better positioned to respond to regional nuances and evolving clinical guidelines. As stakeholders navigate this landscape, continuous alignment between R&D priorities, commercial execution, and patient support will be essential to deliver improved outcomes and long-term value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing clinical adoption of potassium-competitive acid blockers for refractory GERD patients
  • 5.2. Integration of AI-driven digital health platforms for remote monitoring and adherence in GERD therapy
  • 5.3. Expansion of minimally invasive endoscopic reflux barrier techniques such as TIF and MSA in clinical practice
  • 5.4. Emergence of microbiome-targeted therapeutic strategies as adjunctive approaches for GERD management
  • 5.5. Personalized treatment algorithms leveraging genetic biomarkers to optimize GERD therapeutic outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastroesophageal Reflux Disease Therapeutics Market, by Treatment Type

  • 8.1. Antacids
  • 8.2. H2 Receptor Antagonists
    • 8.2.1. Branded
    • 8.2.2. Generic
  • 8.3. Prokinetics
  • 8.4. Proton Pump Inhibitors
    • 8.4.1. Branded
    • 8.4.2. Generic

9. Gastroesophageal Reflux Disease Therapeutics Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Gastroesophageal Reflux Disease Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Gastroesophageal Reflux Disease Therapeutics Market, by Dosage Form

  • 11.1. Capsule
  • 11.2. Liquid
  • 11.3. Suspension
  • 11.4. Tablet

12. Gastroesophageal Reflux Disease Therapeutics Market, by Patient End User

  • 12.1. Home Care Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Gastroesophageal Reflux Disease Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gastroesophageal Reflux Disease Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gastroesophageal Reflux Disease Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AstraZeneca PLC
    • 16.3.2. Takeda Pharmaceutical Company Limited
    • 16.3.3. Johnson & Johnson Services, Inc.
    • 16.3.4. Pfizer Inc.
    • 16.3.5. Sanofi S.A.
    • 16.3.6. GlaxoSmithKline plc
    • 16.3.7. Bayer AG
    • 16.3.8. Merck Sharp & Dohme Corp.
    • 16.3.9. Novartis AG
    • 16.3.10. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 260. ASI